Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus placebo based on PFS as measured using RECIST 1.1 criteria
Critère d'inclusion
- Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)